Study of ultrasound detected residual synovitis treated with combination of anti-rheumatic therapy and denosumab in rheumatoid arthritis

Study of ultrasound detected residual synovitis treated with combination of anti-rheumatic therapy and denosumab in rheumatoid arthritis - Study of ultrasound detected residual synovitis in rheumatoid arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028376

Enrollment

Registered

2017-08-01

Start date

2017-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Combination of anti-rheumatic therapy and denosumab Anti-rheumatic therapy alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who are satisfied the criteria below: 1) Patients who are satisfied American College of Rheumatology (ACR) 1987 RA classification criteria and/or 2010 ACR/Eulopean League Against Rheumatism (EULAR) classification criteria 2) Patients diagnosed as active state of RA according to clinical information 3) Patients who need to start or adjust anti-rheumatic therapy 4) Patients are informed of this protocol and consented to participated

Exclusion criteria

Exclusion criteria: Patients who fulfill one of the following criteria must be excluded: 1) Patients who have apparent infection 2) Female patients who are during pregnancy or lactation 3) Patients who are judged to be inappropriate by investigator

Design outcomes

Primary

Measure	Time frame
Joint ultrasonography and clinical assessments are examined at the baseline, 8th, 16th, 24 and 52nd week. Magnetic resonance imaging of finger joints and X-ray are performed at the baseline, 24th and 52nd week.	—

Countries

Japan

Contacts

Public ContactJun Fukae

Hokkaido Medical Center for Rheumatic Diseases Center for Rheumatic Diseases

jun.fukae@ryumachi-jp.com011-611-1371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026